Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Stopping completely, or trying to self-taper your dosage, could result in worse withdrawal symptoms or side effects
Proper guidance ensures that treatment is both effective and safe
In the SURPASS-2 trial published in the New England Journal of Medicine, participants treated with tirzepatide (5 mg, 10 mg, or 15 mg weekly) experienced reductions in fasting triglycerides from baseline over 40 weeks, with greater reductions generally seen at higher doses
To view or add a comment, sign in FDA announced the first nine recipients of priority review vouchers, which offers expedited drug review to products aligned with national health priorities
Dual-peptide formulation for synergistic research applications BPC-157: studied for tissue-protective and cytoprotective signalling pathways TB-500: investigated for roles in cell migration and angiogenesis Flexible volume delivery with four increment options Extended stability formulation What Researchers Say Frequently Asked Questions A dual-peptide formulation of BPC-157 (a gastric-juice-derived pentadecapeptide) and TB-500 (synthetic Thymosin Beta-4), both studied in preclinical tissue-repair, angiogenesis, and matrix-remodelling research
